

# Alberto Zanetto

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5618688/alberto-zanetto-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73  
papers

880  
citations

18  
h-index

25  
g-index

80  
ext. papers

1,222  
ext. citations

5  
avg. IF

4.52  
L-index

#	Paper	IF	Citations
73	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	7
72	Letter to the Editor: is PAI-1 a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , <b>2022</b> ,	11.2	
71	Hemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications.. <i>Liver International</i> , <b>2022</b> ,	7.9	3
70	Recurrence of the Primary Liver Disease <b>2022</b> , 389-409		
69	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , <b>2022</b> , 100493	10.3	1
68	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	7
67	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 26-37	3	3
66	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	12
65	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67,	3	3
64	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67,	3	1
63	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	21
62	Hepatic benefits of HCV cure: Don't forget coagulation!. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 967-968	13.4	3
61	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , <b>2021</b> , 34, 1325-1327	3	0
60	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , <b>2021</b> , 73, 1275-1289	11.2	20
59	Reduced Clot Stability by Thromboelastography as a Potential Indicator of Procedure-Related Bleeding in Decompensated Cirrhosis. <i>Hepatology Communications</i> , <b>2021</b> , 5, 272-282	6	13
58	Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study. <i>Transplant International</i> , <b>2021</b> , 34, 743-753	3	1
57	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , <b>2021</b> , 41, 2455-2466	7.9	10

56	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 879-888	3.3	6
55	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1987-2000	6	7
54	New Indications for Liver Transplantation. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
53	Recent Advances in the Management of Acute Variceal Hemorrhage. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
52	Reply to "Acute kidney injury in patients with decompensated cirrhosis". <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1217-1218	3.3	0
51	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , <b>2021</b> , 134, 1278-1285.e2	2.4	6
50	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , <b>2021</b> , 67, 4-10	3	2
49	Influence of donor and recipient gender on liver transplantation outcomes in Europe. <i>Liver International</i> , <b>2020</b> , 40, 1961-1971	7.9	6
48	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features. <i>Hepatology</i> , <b>2020</b> , 72, 1327-1340	11.2	28
47	Perioperative management of antithrombotic treatment. <i>Baillieres Best Practice and Research in Clinical Anaesthesiology</i> , <b>2020</b> , 34, 35-50	4	3
46	History of Budd-Chiari Syndrome <b>2020</b> , 1-14		
45	Gastroesophageal Variceal Bleeding Management <b>2020</b> , 39-66		1
44	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 188-194	3.4	8
43	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1173-1181	7	16
42	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , <b>2020</b> , 40, 913-920	7.9	6
41	Management of acute variceal hemorrhage. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	12
40	Milestones in the discovery of Budd-Chiari syndrome. <i>Liver International</i> , <b>2019</b> , 39, 1180-1185	7.9	9
39	Management of Thrombosis in the Liver Transplant Candidate <b>2019</b> , 119-146		

38	Long-term care of transplant recipients: de novo neoplasms after liver transplantation. <i>Current Opinion in Organ Transplantation</i> , <b>2018</b> , 23, 187-195	2.5	19
37	Organ Preservation in Liver Transplantation. <i>Seminars in Liver Disease</i> , <b>2018</b> , 38, 260-269	7.3	12
36	Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. <i>Cancers</i> , <b>2018</b> , 10,	6.6	18
35	Hemodynamic Evaluation of Nonselective $\alpha$ -Blockers in Patients with Cirrhosis and Refractory Ascites. <i>Gastroenterology Research and Practice</i> , <b>2018</b> , 2018, 4098210	2	4
34	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , <b>2018</b> , 38, 2210-2218	7.9	26
33	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 4403-4411	5.6	18
32	Management of bacterial infection in the liver transplant candidate. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 222-230	3.4	13
31	Hepatitis B and liver transplantation. <i>Minerva Gastroenterology</i> , <b>2018</b> , 64, 147-157	3	2
30	Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. <i>Liver International</i> , <b>2018</b> , 38, 1316-1321	7.9	5
29	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , <b>2018</b> , 10,	6.6	33
28	Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis. <i>Transplant International</i> , <b>2018</b> , 31, 1318-1329	3	57
27	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 440-445	3.3	45
26	Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation. <i>Transplant International</i> , <b>2017</b> , 30, 239-242	3	1
25	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 241-253	3.3	18
24	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , <b>2017</b> , 23, 1103-1112	4.5	37
23	Reply. <i>Liver Transplantation</i> , <b>2017</b> , 23, 1630-1631	4.5	
22	Extending transplantation criteria for hepatocellular carcinoma. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 546-547	18.8	
21	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 1168-1176	3.4	18

20	Current challenges and future directions for liver transplantation. <i>Liver International</i> , <b>2017</b> , 37, 317-327	7.9	46
19	Acute alcoholic hepatitis and liver transplantation: Waiting for Godot. <i>Liver International</i> , <b>2017</b> , 37, 1408-7	7.9	1
18	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172159	3.7	31
17	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185728	3.7	28
16	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , <b>2016</b> , 29, 135-53	5.3	8
15	Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. <i>Transplant International</i> , <b>2016</b> , 29, 694-7	3	3
14	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , <b>2016</b> , 143, 118-21	8.2	21
13	New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation. <i>Annals of Transplantation</i> , <b>2016</b> , 21, 632-643	1.4	5
12	Recent advances in understanding and managing liver transplantation. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	16
11	Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 253-9	1.2	3
10	Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 1012-8	3.4	4
9	Liver transplantation for viral hepatitis in 2015. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 1570-81	5.6	30
8	Therapeutic approaches for portal biliopathy: A systematic review. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 9909-9920	5.6	26
7	Assessment of Bleeding Risk in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , <b>2015</b> , 14, 9-18	1	3
6	Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. <i>Platelets</i> , <b>2015</b> , 26, 577-82	3.6	12
5	HCC criteria for liver transplantation: Controversies. <i>Liver Transplantation</i> , <b>2015</b> , 21 Suppl 1, S27-31	4.5	2
4	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. <i>Thrombosis Research</i> , <b>2015</b> , 135, 292-7	8.2	19
3	Markers of acute rejection and graft acceptance in liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 1061-8	5.6	41

- 2 Hepatitis C virus infection in end-stage renal disease and kidney transplantation. *Transplant International*, **2014**, 27, 877-91 3 17
- 1 The role of TIPS in patients with cirrhosis and ascites: recent evolution and open questions. *Hepatology*, 11.2 0